GILDA MARK: Open Payments
NPI 1700124617 · FORT COLLINS, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,673 in 65 payments from 9 companies in 2025. Trend: 2023 $2,097 · 2024 $2,030 · 2025 $2,673
Food & beverage: $2,607Education: $66
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 15 | $867 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 20 | $729 |
| Alkermes, Inc. | 9 | $410 |
| E.R. Squibb & Sons, L.L.C. | 8 | $296 |
| Teva Pharmaceuticals USA, Inc. | 7 | $202 |
| Otsuka America Pharmaceutical, Inc. | 3 | $82 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $44 |
| ABBVIE INC. | 1 | $25 |
| Janssen Scientific Affairs, LLC | 1 | $18 |
Products named: INGREZZA, CAPLYTA, COBENFY, LYBALVI, ARISTADA, AUSTEDO XR, ABILIFY ASIMTUFII, REXULTI.
Industry payments across CO — which companies pay providers there.
